



ERIC HOLCOMB, GOVERNOR  
STATE OF INDIANA

*Office of Medicaid Policy and Planning*  
MS 07, 402 W. WASHINGTON STREET, ROOM W382  
INDIANAPOLIS, IN 46204-2739

## MEETING AGENDA AND PUBLIC NOTIFICATION

Therapeutics Committee  
February 5, 2021  
11:00 A.M.

**Virtual - See information below**

1. Call to Order-Chair
2. Preferred Drug List: Therapeutic Class Re-Review - Discussion and Recommendations
3. Preferred Drug List: Therapeutic Class Re-Review
  - a) Respiratory
    - i. Antihistamine-Decongestant Combinations/2<sup>nd</sup> Generation Antihistamines
    - ii. Antiviral Monoclonal Antibodies
    - iii. Beta Adrenergics and Corticosteroids
    - iv. Beta Agonists
    - v. Bronchodilator Agents - Beta Adrenergic and Anticholinergic Combinations
    - vi. Leukotriene Receptor Antagonists
    - vii. Monoclonal Antibodies for the Treatment of Respiratory Conditions
    - viii. Nasal Antihistamines/Nasal Anti-Inflammatory Steroids
    - ix. Oral Inhaled Glucocorticoids
    - x. Phosphodiesterase-4 Inhibitors



xi. Pulmonary Antihypertensives

b) Anti-Infectives

- i. Antivirals - Anti-Herpetic Agents
- ii. Antivirals - Influenza Agents
- iii. Cephalosporins - 3<sup>rd</sup> Generation
- iv. Fluoroquinolones
- v. Hepatitis C Agents
- vi. Macrolides
- vii. Ophthalmic Antibiotics
- viii. Ophthalmic Antibiotics/Corticosteroid Combinations
- ix. Oral Non-Systemic Antifungals
- x. Otic Antibiotics
- xi. Systemic Antifungals
- xii. Topical Antifungals
- xiii. Topical Antivirals
- xiv. Topical Antivirals and Anti-Inflammatory Steroid Combinations
- xv. Vaginal Antimicrobials

c) Cardiovascular

- i. Angiotensin-Converting Enzyme (ACE) Inhibitors
- ii. ACE Inhibitor Combinations
- iii. Alpha Adrenergic Blockers
- iv. Angiotensin II Receptor Antagonists (ARBs)
- v. ARB Combinations
- vi. Beta Adrenergic Blockers
- vii. Beta Adrenergic Blockers with Diuretics
- viii. Calcium Channel Blockers (CCBs)
- ix. CCBs with HMG-CoA Reductase Inhibitors
- x. Miscellaneous Cardiac Agents

d) Lipotropics

- i. Bile Acid Sequestrants
  - ii. Fibric Acid Derivatives
  - iii. HMG-CoA Reductase Inhibitors
  - iv. Lipotropics
- e) Antimigraine Agents
  - f) Electrolyte Depleters
  - g) Multiple Sclerosis Agents
- 4. Public Comment
  - 5. Other Business
  - 6. Adjourn

## Microsoft Teams meeting

**Join on your computer or mobile app**

[Click here to join the meeting](#)

[https://teams.microsoft.com/l/meetup-join/19%3ameeting\\_OGQ5Y2ZhODItNWNjOC00YmEyLTg4ZjMtODg0N2U3ODkwNjRh%40thread.v2/0?context=%7b%22Tid%22%3a%22db05faca-c82a-4b9d-b9c5-0f64b6755421%22%2c%22Oid%22%3a%2253df74d0-e68c-46fe-81f5-fac4b0bd8ef8%22%7d](https://teams.microsoft.com/l/meetup-join/19%3ameeting_OGQ5Y2ZhODItNWNjOC00YmEyLTg4ZjMtODg0N2U3ODkwNjRh%40thread.v2/0?context=%7b%22Tid%22%3a%22db05faca-c82a-4b9d-b9c5-0f64b6755421%22%2c%22Oid%22%3a%2253df74d0-e68c-46fe-81f5-fac4b0bd8ef8%22%7d)

**Or call in (audio only)**

[+1 952-222-7450](tel:+19522227450),550964097# United States, Bloomington

Phone Conference ID: 550 964 097#